Special article:

Adult ADD examined

A developmental phase, not a permanent disease

Last month’s special article focused on childhood ADD.  We come now to adult ADD.  

It is worth noting that the concept hardly existed before Eli Lilly marketed the drug Strattera (atomoxetine) for it about a decade ago. Before then, the general consensus of researchers was that ADD did not persist into adulthood in the vast majority of persons. 9 prospective studies were conducted before Strattera came to the US market in 2003; in a total of 718 persons followed for 13-25 years from childhood into adulthood, from a mean of age 10 to age 25, the prevalence of ADD fell by 90%. In other words, only 10% of children with ADD continued to have it in their mid 20s.  This observation contrasts with the common opinion these days that the majority of children with ADD will continue to have it as adults. Post-strattera research...

To the complete article, click here or subscribe!

Meet our expert EDITORIAL BOARD, composed of clinicians and researchers from around the world. 

Subscribe to the RSS feed below to follow our "What's new" blog posts